Background The complicated cellular and biochemical changes that occur in brain during
Alzheimer's disease are poorly understood. In a previous study we used an unbiased label …

Abstract Amyloid-beta 42 (Aβ42) and phosphorylated tau (pTau) levels in cerebrospinal fluid
(CSF) reflect core features of the pathogenesis of Alzheimer's disease (AD) more directly …

Scientific advances over the last four decades have steadily infused the Alzheimer's disease
(AD) field with great optimism that therapies targeting Aβ, amyloid, tau, and innate immune …

Genome-wide studies have identified genetic variants linked to neurologic diseases.
Environmental factors also play important roles, but no methods are available for their …

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the main cause
of dementia among the elderly worldwide. Despite intense efforts to develop drugs for …

Alzheimer's disease (AD) is the leading cause of dementia worldwide. The extracellular
deposits of Amyloid beta (Aβ) in the brain—called amyloid plaques, and neurofibrillary …

To date, the development of disease-modifying therapies for Alzheimer's disease (AD) has
largely focused on the removal of amyloid beta Aβ fragments from the CNS. Proteomic …

Microglia are the predominant immune response cells and professional phagocytes of the
central nervous system (CNS) that have been shown to be important for brain development …

Alzheimer's disease (AD) is a progressive, neurodegenerative disorder that is characterized
by neurodegeneration, cognitive impairment, and an eventual inability to perform daily tasks …

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by protein
aggregation in the brain. Recent studies have revealed the critical role of microglia in AD …